[go: up one dir, main page]

MX2017006813A - Composicion farmaceutica, preparacion y usos de la misma. - Google Patents

Composicion farmaceutica, preparacion y usos de la misma.

Info

Publication number
MX2017006813A
MX2017006813A MX2017006813A MX2017006813A MX2017006813A MX 2017006813 A MX2017006813 A MX 2017006813A MX 2017006813 A MX2017006813 A MX 2017006813A MX 2017006813 A MX2017006813 A MX 2017006813A MX 2017006813 A MX2017006813 A MX 2017006813A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compound
nanoparticle
subject
pharmaceutical composition
preparation
Prior art date
Application number
MX2017006813A
Other languages
English (en)
Inventor
Levy Laurent
Meyre Marie-Edith
Pottier Agnès
Original Assignee
Nanobiotix
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanobiotix filed Critical Nanobiotix
Publication of MX2017006813A publication Critical patent/MX2017006813A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que comprende la combinación de (i) al menos una nanopartícula biocompatible y de (ii) al menos un compuesto farmacéutico, para administrarse a un sujeto que necesite dicho compuesto farmacéutico, en donde las nanopartículas potencian la eficacia del compuesto farmacéutico. La dimensión más larga de la nanopartícula biocompatible es típicamente entre aproximadamente 4 y aproximadamente 500 nm, su valor absoluto de carga superficial es de al menos 10 mV (|10 mV|), y su módulo de Young es menor que 100 kPa. La invención también se refiere a dicha composición para usarse para administrar el compuesto farmacéutico en un sujeto que lo necesite, en el que la al menos una nanopartícula y el al menos un compuesto farmacéutico se administren en el sujeto entre más de 5 minutos y aproximadamente 72 horas uno del otro.
MX2017006813A 2014-11-25 2015-11-24 Composicion farmaceutica, preparacion y usos de la misma. MX2017006813A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14306873 2014-11-25
PCT/EP2015/077438 WO2016083336A1 (en) 2014-11-25 2015-11-24 Pharmaceutical composition, preparation and uses thereof

Publications (1)

Publication Number Publication Date
MX2017006813A true MX2017006813A (es) 2018-01-30

Family

ID=52013980

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006813A MX2017006813A (es) 2014-11-25 2015-11-24 Composicion farmaceutica, preparacion y usos de la misma.

Country Status (16)

Country Link
US (1) US20170258718A1 (es)
EP (1) EP3229781A1 (es)
JP (1) JP2018500298A (es)
KR (1) KR20170086638A (es)
CN (1) CN107106505A (es)
AR (1) AR102779A1 (es)
AU (1) AU2015352688A1 (es)
BR (1) BR112017010933A2 (es)
CA (1) CA2968473A1 (es)
EA (1) EA201791138A1 (es)
HK (1) HK1245086A1 (es)
IL (1) IL252397A0 (es)
MX (1) MX2017006813A (es)
SG (1) SG11201704143YA (es)
TW (1) TW201628639A (es)
WO (1) WO2016083336A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ714273A (en) 2013-05-30 2019-04-26 Nanobiotix Pharmaceutical composition comprising the combination of a biocompatible nanoparticle and a compound of interest, preparation and uses thereof
EP3229776B1 (en) 2014-11-25 2023-06-28 Curadigm Sas Pharmaceutical composition combining at least two distinct nanoparticles and a pharmaceutical compound, preparation and uses thereof
NZ769187A (en) 2014-11-25 2023-07-28 Curadigm Sas Pharmaceutical composition, preparation and uses thereof
ES2890662T3 (es) 2014-11-25 2022-01-21 Curadigm Sas Composiciones farmacéuticas, preparación y usos de las mismas
EP3229843B1 (en) 2014-11-25 2020-01-01 Curadigm Sas Pharmaceutical composition, preparation and uses thereof
JP2018516256A (ja) 2015-05-28 2018-06-21 ナノビオティックスＮａｎｏｂｉｏｔｉｘ 治療用ワクチンとしての使用のためのナノ粒子
PT3727349T (pt) * 2017-12-19 2024-10-31 Nanobiotix Nanopartículas para utilização no tratamento de um distúrbio neuronal

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5513708B2 (ja) 2003-12-22 2014-06-04 ブラッコ・シュイス・ソシエテ・アノニム 造影イメージング用の気体封入マイクロベシクル・アセンブリー
JP2007523090A (ja) * 2004-02-10 2007-08-16 バーンズ−ジューイッシュ ホスピタル デコイ系を用いたターゲティングされた微粒子剤の有効性および安全性の改善方法
EP2000150B1 (en) * 2006-03-24 2016-07-13 Toto Ltd. Titanium oxide complex particle, dispersion solution of the particle, and process for production of the particle
EP1852107A1 (en) 2006-04-19 2007-11-07 Nanobiotix Magnetic nanoparticles compositions and uses thereof
EP2130553A1 (en) 2008-06-05 2009-12-09 Nanobiotix Inorganic nanoparticles of high density to destroy cells in-vivo
WO2012104277A2 (en) * 2011-01-31 2012-08-09 Nanobiotix Method of monitoring the release from liposomes of a product of interest using superparamagnetic nanoparticles.
WO2012104275A2 (en) * 2011-01-31 2012-08-09 Nanobiotix Nanoparticles delivery systems, preparation and uses thereof
ITRM20120480A1 (it) * 2012-10-09 2014-04-10 Uni Degli Studi Camerino Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione.

Also Published As

Publication number Publication date
EA201791138A1 (ru) 2017-09-29
US20170258718A1 (en) 2017-09-14
AU2015352688A1 (en) 2017-07-13
BR112017010933A2 (pt) 2018-02-14
IL252397A0 (en) 2017-07-31
SG11201704143YA (en) 2017-06-29
JP2018500298A (ja) 2018-01-11
AR102779A1 (es) 2017-03-22
CN107106505A (zh) 2017-08-29
WO2016083336A1 (en) 2016-06-02
EP3229781A1 (en) 2017-10-18
HK1245086A1 (zh) 2018-08-24
CA2968473A1 (en) 2016-06-02
KR20170086638A (ko) 2017-07-26
TW201628639A (zh) 2016-08-16

Similar Documents

Publication Publication Date Title
NZ714273A (en) Pharmaceutical composition comprising the combination of a biocompatible nanoparticle and a compound of interest, preparation and uses thereof
MX2017006813A (es) Composicion farmaceutica, preparacion y usos de la misma.
MX2019015578A (es) Metodos para tratar la enfermedad de huntington.
MX2019015580A (es) Metodos para tratar la enfermedad de huntington.
WO2017042607A3 (en) Compositions comprising meloxicam-cyclodextrin inclusion complexes and methods of treating acute pain
MY196319A (en) Polycyclic TLR7/8 Antagonists and use Thereof in the Treatment of Immune Disorders
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
MX355065B (es) Método y dispositivo para conmutación de cámaras.
MX2021010595A (es) Composicion farmaceutica, preparacion y usos de la misma.
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
MX2016005668A (es) Formas cristalinas de compuestos terapeuticos y sus usos.
WO2016025933A3 (en) Substituted polycyclic antibacterial compounds
AR092993A1 (es) Laquinimod para reducir el daño talamico en la esclerosis multiple
WO2014205199A3 (en) Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency
SG10201907291QA (en) Monomethylfumarate prodrug compositions
PH12016501519A1 (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
PH12015502747A1 (en) Novel compounds for the treatment of cancer
NZ757526A (en) Naphthoquinones, their derivatives and uses thereof in methods for the treatment of mitochondrial dysfunction
MX2019012375A (es) Formulaciones del inhibidor del antigeno-1 asociado a la funcion de linfocitos (lfa-1).
EA201890075A1 (ru) Инъецируемые фармацевтические композиции лефамулина
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
WO2016040814A3 (en) Disulfide polymers and methods of use
IN2013MU01177A (es)
PH12015502727A1 (en) Methods and compositions for enhancing cognitive performance
TR201905694T4 (tr) Aripiprazol ön ilaç bileşimleri.